Login
Super Investors THE ARBITRAGE FUND

THE ARBITRAGE FUND

Arbitrage Funds · net assets $882M · 98 holdings as of August 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.

Asset mix

EC: 95.4% · OTHER: 3.4% · STIV: 1.0% · DE: 0.4% · DFE: -0.2%

Financial position

Total assets
$923M
Total liabilities
$41.1M
Net assets
$882M
Assets attributable to miscellaneous securities
$0
Assets invested in controlled foreign corporations
$0
Borrowings payable within one year
$0
Payable to controlled companies within one year
$0
Payable to other affiliates within one year
$0
Other liabilities payable within one year
$0
Borrowings payable after one year
$0
Payable to controlled companies after one year
$0
Payable to other affiliates after one year
$0
Other liabilities payable after one year
$0
Payables for delayed-delivery investments
$0
Payables for standby commitments
$0
Liquidation preference of outstanding preferred stock
$0
Cash not reported in Parts C or D
$0

Monthly flows and gains

Month 1 Month 2 Month 3
Sales $12.6M $24.8M $17.2M
Reinvestment $0 $0 $0
Redemptions $9.45M $9.02M $10.8M
Net realized gain (non-derivative) $-740K $8.75M $3.68M
Net unrealized appreciation (non-derivative) $6.6M $-1.36M $1.08M

The three months of the reporting period, as filed; month 3 ends August 31, 2026.

Filing details

Registrant
Arbitrage Funds
Registrant CIK
1105076
Registrant LEI
549300NPBJYDNFZ58M30
Series
THE ARBITRAGE FUND
Series ID
S000006440
Series LEI
5ID2Z4T6QF54X8TFRS62
SEC file number
811-09815
Address
C/O WATER ISLAND CAPITAL, LLC, 104 FIFTH AVENUE, 9TH FLOOR, NEW YORK, US-NY, 10011, US
Phone
800-560-8210
Form
NPORT-P
Filed
October 20, 2026
Report period ends
May 31, 2027
Report month ends
August 31, 2026
Accession number
000141036826106369
Holding Value % of net assets
Penumbra Inc EC $58.9M 6.68%
Txnm Energy Inc EC $48.1M 5.46%
Silicon Laboratories Inc EC $44.8M 5.08%
Norfolk Southern Corp EC $43.3M 4.91%
Warner Bros Discovery Inc EC $43M 4.87%
Liveramp Holdings Inc EC $41.5M 4.71%
Caesars Entertainment Inc EC $40.5M 4.59%
Dominion Energy Inc EC $38.4M 4.36%
Endeavor Group Holdings Inc EC $33.8M 3.84%
Bio-techne Corp EC $32.7M 3.71%
Arcosa Inc EC $31.2M 3.54%
Roku Inc EC $30.7M 3.47%
Morgan Stanley Prime Broker Us OTHER $29.6M 3.35%
Schroders PLC EC $28.8M 3.26%
Water Island Event Driven Fund EC $27.9M 3.17%
Lxp Industrial Trust EC $25.8M 2.93%
Beazer Homes Usa Inc EC $23.9M 2.71%
Intertek Group PLC EC $22.2M 2.52%
Biolife Solutions Inc EC $20.8M 2.35%
Integer Holdings Corp EC $18.1M 2.06%
Doubleverify Holdings Inc EC $17.6M 1.99%
Accelerant Holdings EC $17.6M 1.99%
Marketaxess Holdings Inc EC $17.3M 1.96%
Bowman Consulting Group Ltd EC $13.2M 1.50%
Utz Brands Inc EC $13.2M 1.50%
Marinemax Inc EC $13.2M 1.50%
Atkore Inc EC $13.1M 1.49%
Varex Imaging Corp EC $11M 1.24%
Lantheus Holdings Inc EC $10.9M 1.23%
Kenvue Inc EC $10.8M 1.22%
Element Solutions Inc EC $9.98M 1.13%
Ataibeckley Inc EC $8.91M 1.01%
Weave Communications Inc EC $8.81M 1.00%
Tate & Lyle PLC EC $8.74M 0.99%
Segro PLC EC $8.7M 0.99%
Crinetics Pharmaceuticals Inc EC $8.53M 0.97%
Delivery Hero Se EC $8.36M 0.95%
Beazley PLC EC $8.31M 0.94%
Morgan Stanley & Co. LLC STIV $4.43M 0.50%
State Street Global Advisors STIV $4.43M 0.50%
Skechers Usa Inc EC $4.26M 0.48%
Bowhead Specialty Holdings Inc EC $3.13M 0.36%
Morgan Stanley & Co. LLC DE $1.82M 0.21%
Centessa Pharmaceuticals PLC DE $1.46M 0.16%
Contra Resolute Forest DE $1.26M 0.14%
Bristol-myers Squibb Co DE $1.18M 0.13%
Aspen Technology Inc EC $1.15M 0.13%
Contra Metsera Inc DE $870K 0.10%
Contra Flexion Therape DE $863K 0.10%
Contra Concert Pharmac DE $861K 0.10%
Contra Regulus Therape DE $649K 0.07%
Contra Avadel Pharmace DE $646K 0.07%
Contra Verve Therapeut DE $462K 0.05%
Morgan Stanley & Co. LLC DE $320K 0.04%
Contra Icosavax Inc DE $317K 0.04%
Contra Abiomed Inc DE $262K 0.03%
Contra Xoma Royalty Co DE $235K 0.03%
Contra Treehouse Foods DE $164K 0.02%
Contra Albireo Pharma DE $138K 0.02%
Contra Akero Therapeut DE $137K 0.02%

Showing top 60 of 98 holdings.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support